Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INULIN AND SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inulin is a polysaccharide that is not absorbed from the gastrointestinal tract and is used as a diagnostic agent to measure glomerular filtration rate (GFR) by renal clearance. Sodium chloride provides electrolyte supplementation.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Measurement of glomerular filtration rate (GFR),Diagnostic aid in renal function testing
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Inulin: 5 g IV bolus followed by continuous infusion at 1.5 m L/min of a 10 g/L solution for GFR measurement. Sodium chloride: 0.9% solution as diluent.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Normal renal function: 1.5 hours (range 1–2 h); decreases to 0.5 h with severe renal impairment; used to measure glomerular filtration rate (GFR)
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Inulin is not metabolized; it is excreted unchanged by the kidneys. Sodium chloride is absorbed and distributed; no metabolism.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: 100% as unchanged drug via glomerular filtration without tubular reabsorption or secretion; biliary/fecal: negligible (<1%)
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Approximately 0% (negligible); does not bind to plasma proteins
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.15–0.25 L/kg (approx. 15–25% of body weight; confined to extracellular fluid); reflects distribution limited to extracellular space
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%; oral: <1% (not absorbed; used for oral GFR measurement but bioavailability is negligible)
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Inulin excretion is renal; no dose adjustment as used for GFR measurement. In renal failure, monitor for hypernatremia from Na Cl content.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required; inulin is not hepatically metabolized.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Inulin: 0.5 m L/kg IV bolus of 10% solution followed by infusion at 0.15 m L/kg/min. Sodium chloride: as per isotonic requirement.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use standard dosing; consider reduced GFR in elderly; monitor volume and electrolyte status.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA black box warning.
None.
Use with caution in patients with known anuria or severe renal impairment due to risk of accumulation. Monitor fluid and electrolyte balance.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to inulin; anuria; severe renal impairment.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. Maintain adequate hydration as directed. Avoid excessive salt intake if sodium chloride load is a concern.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Inulin is not absorbed systemically; sodium chloride is physiologic. No known teratogenic risk in any trimester.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Inulin is not absorbed systemically; sodium chloride is normal plasma constituent. M/P ratio not applicable. Considered safe during breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustment needed; pharmacokinetics of inulin and sodium chloride are not altered in pregnancy.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Inulin is an inert polysaccharide used in glomerular filtration rate (GFR) measurement. Administer as a continuous IV infusion to maintain steady-state plasma levels. Avoid extravasation; inulin is non-irritating but high volumes may cause discomfort. Monitor for fluid overload in patients with compromised cardiac function due to sodium chloride content. Use isotonic (0.9%) or half-isotonic solution depending on hydration status.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
You will receive a solution containing inulin and salt through a vein to test your kidney function.,Report any pain, redness, or swelling at the IV site.,You may experience a metallic taste or warmth during infusion; these are temporary.,Stay well hydrated before and after the test unless advised otherwise.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INULIN AND SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
INULIN AND SODIUM CHLORIDE is a Electrolyte that works by Inulin is a polysaccharide that is not absorbed from the gastrointestinal tract and is used as a diagnostic agent to measure glomerular filtration rate (GFR) by renal clearance. Sodium chloride provides electrolyte supplementation.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INULIN AND SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INULIN AND SODIUM CHLORIDE is: Inulin: 5 g IV bolus followed by continuous infusion at 1.5 m L/min of a 10 g/L solution for GFR measurement. Sodium chloride: 0.9% solution as diluent.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining INULIN AND SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. INULIN AND SODIUM CHLORIDE is classified as Category A/B. Inulin is not absorbed systemically; sodium chloride is physiologic. No known teratogenic risk in any trimester.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.